Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This notable drop came on the heels of the company's announcement and pricing of a substantial public stock offering, a move that
The healthcare sector experienced a significant downturn on Thursday, September 25, 2025, shedding a notable -1.67% of its value and sending ripples of concern through the broader financial markets. This sharp decline, which outpaced the overall market's performance, immediately signaled investor apprehension regarding a sector traditionally viewed as defensive
September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025. These new duties, targeting sectors from pharmaceuticals to heavy trucks and home furnishings, signal a deepening
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) announced a $650 million expansion of its U.S. manufacturing network.
AstraZeneca Plc (NASDAQ: AZN) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price w
New York, NY – September 26, 2025 – U.S. stock market futures, including the Dow, S&P 500, and Nasdaq, registered notable advances today, signaling a robust open after the release of August's inflation data. The Personal Consumption Expenditures (PCE) Price Index, the Federal Reserve's preferred inflation gauge, largely matched economists'
President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly Big Pharma, remains displeased.
Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY)
fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was intended to prevent muscle loss in patients taking its blockbuster obesity treatment, Zepbound.
Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July 2025. This ambitious initiative is poised to fundamentally transform humanity's defense against future pandemics and biowarfare threats by leveraging advanced artificial intelligence
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.
